logo

Retrophin Inc. (RTRX)



Trade RTRX now with
  Date
  Headline
9/21/2020 8:15:37 AM Retrophin Says First 280 Patients Enrolled In Pivotal Phase 3 PROTECT Study On Sparsentan
6/8/2020 10:25:14 PM Retrophin Prices Underwritten Public Offering Of 6.50 Mln Shares At $15.50/shr
1/13/2020 7:12:38 AM Retrophin Expects Net Product Sales For Q4 To Be $47 Mln
8/22/2019 6:04:01 AM Retrophin Says FORT Study Did Not Achieve Its Primary Or Secondary Endpoints
5/13/2019 8:06:21 AM Retrophin Appoints Sandra Poole To Board
1/7/2019 7:20:01 AM Retrophin Expects Net Product Sales For Q4 To Be $44 Mln
1/3/2019 5:16:25 PM Retrophin Names Eric Dube President And CEO
12/20/2018 8:08:13 AM Retrophin Completes Enrollment Of Pivotal Phase 3 FORT Study Of Fosmetpantotenate In PKAN
11/12/2018 7:02:51 AM Retrophin Announces FDA Acceptance Of NDA Filing For New Formulation Of Thiola For Cystinuria
7/30/2018 4:34:26 PM Retrophin Appoints Noah Rosenberg As Chief Medical Officer
6/4/2018 8:11:02 AM Retrophin Announces Pivotal Phase 3 FORT Study Of Fosmetpantotenate In PKAN Opens Enrollment To Pediatric Patients
4/3/2018 8:14:53 AM Retrophin Begins Pivotal Phase 3 Clinical Trial Of Sparsentan For Treatment Of Focal Segmental Glomerulosclerosis
3/5/2018 4:33:09 PM Retrophin Appoints Casey Logan As VP Of Corporate Development
1/8/2018 7:18:28 AM Retrophin Expects Net Product Sales For Q4 To Be $42 Mln